Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,963 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,963 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Open enrollment, early-phase tilt
HIV Infections has 615 registered US clinical trials, 56 of them open to new participants right now, about 9% of the total.
- 56
- recruiting participants now
- 9%
- of trials open to enrollment
- 92
- in Phase 3-4 (later-stage)
- 195
- top sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Corpus placement: #7 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 11 of 13
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
Alexion Pharmaceuticals
NCT00312039
Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults
ViiV Healthcare
NCT04425902
The Biology of HIV Transmission
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001092
Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects
VGX Pharmaceuticals
NCT00352911
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Sangamo Therapeutics
NCT01044654
A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000694
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000898
Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00076817
Atazanavir Twice Daily
Bristol-Myers Squibb
NCT00357721
A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001007
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
Merck Sharp & Dohme
NCT00005921
Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
University of California, San Francisco
NCT00672932
A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001008
Life Skills Intervention for Adolescents Perinatally Infected With HIV
University of North Carolina, Chapel Hill
NCT00272519
RAL-eve Study: Raltegravir Substitution Study
Stanford University
NCT00523237
Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone
Bristol-Myers Squibb
NCT00362726
Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00069498
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000749
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
University of North Carolina, Chapel Hill
NCT00855088
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir
Yale University
NCT00486330
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
Rockefeller University
NCT00002392
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000706
A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000852
A Study of Azithromycin in HIV-Infected Patients
Pfizer
NCT00002344
The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001036
A Study of L-735,524 in HIV-Positive Children and Adolescents
Merck Sharp & Dohme
NCT00002351
Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens
Phoenix Children's Hospital
NCT00940771
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001646
A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus
Genzyme, a Sanofi Company
NCT00361101
Evaluation of the Interaction Between Acetaminophen and Zidovudine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000731
Adoptive Transfer of Haploidentical NK Cells and N-803
University of Minnesota
NCT03899480
Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men
Johns Hopkins University
NCT00696618
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression
University of Maryland, Baltimore
NCT00344981
Taste Properties of HIV Inhibitor
ViiV Healthcare
NCT02608918
Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01054872
Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
University of California, San Francisco
NCT00884793
HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals
Catherine Bollard
NCT03485963
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
Alexion Pharmaceuticals
NCT00675844
A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).
National Institute of Mental Health (NIMH)
NCT00000393
Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression
University of Maryland, Baltimore
NCT00336778
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00050856
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00100581
Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy
University of Pennsylvania
NCT00991224
A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
Dupont Merck
NCT00002410
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
Ortho Pharmaceuticals
NCT00002071
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.
The Immune Response Corporation
NCT00002173
A Study of HIV in Newly Infected Individuals
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000930
A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs
Bristol-Myers Squibb
NCT00002308
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
National Cancer Institute (NCI)
NCT00491335
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
Pfizer
NCT00002112
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for HIV Infections right now
56 recruiting of 615 indexed (9% open).
Phase mix: 92 late (III/IV) vs 266 early (I/II) (early-phase heavy).
Top sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (195 trials), 9 others listed. 50 shown below, recruiting first. #7 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for HIV Infections?
PlainTrial tracks 615 US clinical trials for HIV Infections, of which 56 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for HIV Infections?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.